Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis

INTRODUCTION: COVID-19 related mortality is about 2%, and it increases with comorbidities, like hypertension. Regarding management, there is debatable evidence about the benefits of continuation vs. discontinuation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEI/A...

Descripción completa

Detalles Bibliográficos
Autores principales: Chambergo-Michilot, Diego, Runzer-Colmenares, Fernando M., Segura-Saldaña, Pedro A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177739/
https://www.ncbi.nlm.nih.gov/pubmed/37171528
http://dx.doi.org/10.1007/s40292-023-00579-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177739/
https://www.ncbi.nlm.nih.gov/pubmed/37171528
http://dx.doi.org/10.1007/s40292-023-00579-0

Ejemplares similares